Impact of different biochemical markers in serum of patients with benign and malignant liver diseases  by Zakhary, Nadia I. et al.
Journal of Advanced Research (2011) 2, 49–55Cairo University
Journal of Advanced ResearchORIGINAL ARTICLEImpact of diﬀerent biochemical markers in serum
of patients with benign and malignant liver diseasesNadia I. Zakhary a,*, Mahmoud M. El-Merzabani a, Nagwa M. El-Sawi b,
Saleh M. Saleh c, Manar M. Moneer d, Ragaa H. Mohamad ba Cancer Biology Department, National Cancer Institute, Cairo University, Egypt
b Biochemistry Department, Faculty of Medicine, Sohag University, Egypt
c National Liver Institute, Menoﬁa University, Egypt
d Biostatistics and Epidemiology Department, National Cancer Institute, Cairo University, EgyptReceived 5 November 2009; revised 7 June 2010; accepted 21 July 2010
Available online 23 September 2010*
E-
20
El
Pe
doKEYWORDS
Liver diseases;
TNF-a;
EGF;
EGFR;
GST-a;
aFPCorresponding author. Tel.:
mail address: n_i_zakhary@
90-1232 ª 2011 Cairo Un
sevier B.V. All rights reserve
er review under responsibilit
i:10.1016/j.jare.2010.08.001
Production and h+20 123
yahoo.co
iversity.
d.
y of Cair
osting by EAbstract The only hope for effective treatment of liver cancer lies in early detection or screening
for populations who are at high risk for developing liver cancer. This study was designed to study
the levels of a collection of biochemical markers in the sera of patients suffering from hepatocellular
carcinoma (HCC) and its predisposing diseases. The ultimate aim is to investigate their diagnostic
impact in the early detection of HCC and discriminate from benign liver diseases. The study was
carried out on 217 individuals divided into the following groups: Group 1: Normal controls, Group
2: Schistosomal patients (Schist), Group 3: Hepatitis B patients (HBV), Group 4: Hepatitis C
patients (HCV), Group 5: Cirrhotic patients (Cirr), and Group 6: Hepatocellular carcinoma
patients (HCC). The last group was further subdivided into the following subgroups: a – HCC
alone; b – HCC on top of schistosomiasis; c – HCC on top of HBV; d – Hepato-cellular carcinoma
on top of HCV; e – HCC on top of cirrhosis. Their sera were subjected to a quantitative determi-
nation of the tumour necrosis factor-alpha (TNF-a), epidermal growth factor and its receptor (EGF
and EGFR), glutathione-S-transferase alpha (GST-a), iron, ferritin, transferrin, alpha-1-antitrypsin
(a1AT) and alpha-fetoprotein (aFP). The results of this study indicate that it is advisable to deter-761316.
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50 N.I. Zakhary et al.mine a panel of markers composed of aFP, TNF-a and GST-a to conﬁrm diagnosis of HCC and
distinguish it from other benign liver diseases.
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In Egypt, digestive-system malignancies rank as the forth most
common cancer, following the lympho-hematopoietic system,
the breast and the urinary bladder. They contribute to
13.5% of total malignancies with a slight male predominance
of 54.6% and a high adult-age predominance of 96.6%. Liver
cancer forms more than 11.8% of these malignancies, about
70.5% of which are HCC [1]. HCC is multifactorial in origin
and a number of causal associations have been identiﬁed.
These may be divided into major and minor risk factors. The
major risk factors include chronic HBV and HCV infection,
which are represented in 70–95% of HCC patients [2], chronic
necro-inﬂammatory hepatic disease, commonly in the form of
cirrhosis, which is represented in 60–80% of patients [3]. HCC
occurs in cirrhotic patients associated with HBV infection.
However, 10–25% of cases developed in the absence of cirrho-
sis. This is due to the direct oncogenic effect of HBV as in the
HBV-DNA genome, which integrates with hepatocellular
chromosomes [4]. In contrast to HBV, HCV cannot integrate
into the host genome. It exerts its effect, most probably,
through production of cirrhosis with severe liver damage [5].
Many recent studies have shown that HCV has a direct onco-
genic action through its core component [6]. Aﬂatoxin B1 is
the most potent chemical known to cause HCC. It is a product
of a mould called Aspergillus ﬂavus, which grows in oily seeds
that have been stored in a hot and humid environment, such as
peanuts, soybeans, corn and wheat. It is thought to cause can-
cer via mutations in the p53 gene, by interfering with its tu-
mour suppressing functions [7].
Minor risk factors include oral steroidal contraceptives
and androgens that are associated with the development of
hepatic adenomas, which have the potential to become malig-
nant. It also includes cigarette smoking, membranous
obstruction of the inferior vena cava, and a variety of mostly
rare inherited metabolic diseases, particularly hereditary hae-
mochromatosis [8].
Both HCV and HBV infection are the most common risk
factors of HCC among Egyptian patients. About 10–20% of
the general Egyptian population is infected with HCV [9].
Approximately 90% of Egyptian HCV isolates belong to a sin-
gle subtype, 4a, which responds less successfully to interferon
therapy than other subtypes [10]. Farmers who are exposed
to chemicals during their work, such as insecticides, herbicides,
pesticides and fertilizers are very likely to develop hepatoma.
Schistosomiasis also increased the severity of HBV infection
and elevated the risk of HCC over that associated with the
HBV infection alone. Other factors associated with an in-
creased risk of HCC in Egypt include cigarette smoking and
occupational exposure to chemicals [11–13].
Liver cancer grows silently and does not cause symptoms
until the disease is advanced, at which time there is little chance
for recovery, and life expectancy is usually in the range of a few
months. Therefore, the only hope of effective treatment lies in
early detection with screening of high-risk populations. Two
tests are commonly used to screen for liver cancer, namelyan ultrasound examination of the liver and analysis of serum
level of aFP [14]. Both tests have advantages and disadvan-
tages. The aFP is easier to do and less expensive. However,
it is not 100% speciﬁc and sensitive, since minor elevations
are common in patients with chronic liver disease, pregnancy
and germ cell tumours. Titers also rise with ﬂares of active hep-
atitis, and may be persistently elevated in patients with cirrho-
sis [15]. Ultrasound is better, but more expensive, very
operator dependent and less reliable in the presence of cirrho-
sis, missing a signiﬁcant number of cancers. New screening of
serum markers is under evaluation. None of them have yet
been conclusively diagnostic.
This study was designed to determine the levels of several
tumour markers in sera of patients suffering from HCC and
other benign predisposing diseases, namely schistosomiasis,
chronic active hepatitis B and C, as well as cirrhosis. The ulti-
mate goal of the study is to ﬁnd a panel of markers that would
improve the early detection of HCC and screen for those who
are at high risk for the disease, as well as distinguishing HCC
from other benign liver lesions.
Subjects and methods
This work is a prospective study that lasted 18 months and
started in December 2006. Two hundred and seventeen indi-
viduals were included in this study. They were selected from
the out-patient clinic of the Department of Internal Medicine,
National Liver Institute, Menouﬁa University, and the
Department of Medical Oncology, National Cancer Institute,
Cairo University. Patients were informed via documented con-
sent. The ethical committee (IRD) of the NCI, Cairo Univer-
sity, approved the study in November 2006. This committee
follows the Helsinki ethical rules.
Individuals under investigation were divided into the fol-
lowing groups:
Group 1: Normal control group, including 17 apparently
healthy individuals. They were healthy volunteers including
the working team, their relatives, friends and colleagues.
Group 2: Schistosomal group, including 40 patients suffer-
ing of Schistosoma mansoni infestation.
Group 3: HBV group, including 40 patients infected with
HBV.
Group 4: HCV group, including 40 patients infected with
HCV.
Group 5: Cirrhotic group, including 40 patients suffering
from liver cirrhosis without viral infection.
Group 6: HCC group, including 40 patients.
All patients were subjected to clinical and radiological
examination to conﬁrm their diagnosis. Sera were collected
from all groups and subjected to quantitative determination
of the following biochemical parameters:
1. TNF-a was determined by ELISA technique, using a kit
provided by Immunogenetics Company, Belgium.
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kine Immunoassay kit, USA.
3. EGFR was determined by ELISA technique, using a Cal-
biochem Immunoassay kit, USA.
4. GST-a was determined by ELISA technique, using a Hep
kit from Brotrin International, Ireland.
5. Iron was determined by chemiluminescence, using a Senti-
nel kit, Italy.
6. Ferritin was determined by ELISA technique, using a Quo-
rum ElA kit, Canada.
7. Transferrin was determined by ELISA technique, using the
SPQTM antibody reagent SET2 for transferring, from
INCSTAR Corporation, USA.
8. a1AT was determined by chemiluminescence, using the
SPQTM antibody reagent SET2 for a1AT, from INC-
STAR Corporation, USA.
9. a FP was determined by ELISA technique, using a Quorum
Ela Kit, Canada.
Statistical methods
Sample size was estimated to include 15 cases for each group at
an alpha error of 0.05 and a power of the study of 95%. This
depends on the difference between cirrhotic and HCC patients
in the level of TNF-a. We included more cases in each disease
group, owing to the multiplicity of markers as well as the large
number of groups. Data were analyzed using SPSS version 15.
Numerical data were expressed as median and range. For
quantitative data, comparison between the six groups was
done using a Kruskal–Wallis test followed by a Schefe test
on the ranks of different variables for pair-wise comparison
of HCC against other groups. An ROC curve was used to de-
duce the most appropriate cut-off levels of all markers for
diagnosis of HCC. A p-value < 0.05 was considered signiﬁ-
cant [16].Table 1 Clinico-pathological features of individual in different gro
Parameter Control Schist* HC
Number 17 17 40
Male 12 34 33
Female 5 6 1
Age 39.7 ± 6.4 44 ± 7 44 ±
(30–52) (30–55) (25–
Alk phase 36.8 ± 8.3 32.5 ± 8.1 62.7
(22–52) (15–53) (20–
sGOT 15.4 ± 5.8 25 ± 8.4 57 ±
(8–29) (18–54) (25–
sGPT 14.3 ± 4.3 35.5 ± 13.1 44 ±
(13–25) (15–71) (8–7
Tot. bilirubin 0.5.3 ± 0.2 0.7 ± 0.2 0.9 ±
(0.2–0.8) (0–1.3) (2.2
HCV +ve cases 0 0 40
HBV +ve cases 0 0 0
Hematemesis +ve cases 0 0 12
Ascitis +ve cases 0 0 9
Grade I
Grade II
Grade III
Data are expressed as mean ± SD and number of cases.
Data between parentheses represents the range.
* Schist and Cirr are referred to Schistosomal and Cirrhotic group, respeResults
Table 1 shows the number, gender and clinical-pathologi-
cal features of individuals from all groups under investi-
gation.
Table 2 illustrates the changes in different parameters to the
median levels as well as their range in the different groups
studied. Signiﬁcant elevations were observed in the levels of
TNFa, GST-a and aFP in the disease groups, giving a tremen-
dous increase in the HCC group. The levels of EGF and
EGFR were signiﬁcantly lower in sera of all disease groups
as compared with the control group. Both markers were signif-
icantly higher in HCC patients compared with the other dis-
ease groups. Serum iron concentration in patients with HBV,
HCV and cirrhosis was signiﬁcantly higher than the control,
Schist and HCC groups. Cases with hepatitis had signiﬁcantly
higher ferritin as compared with other groups. Transferrin
levels were signiﬁcantly lower in the HCC group compared
with other disease groups. Serum levels of aIAT were signiﬁ-
cantly higher in the HCC group relative to the other disease
groups.
Tables 3–5 show the AUC, cut-off values, sensitivities
and speciﬁcities of the different parameters investigated.
The TNFa, EGFR, GST-a and aFP gave the best sensitiv-
ities and speciﬁcities for the control group versus HCC.
However, the best sensitivities and speciﬁcities for the benign
liver diseases taken collectively versus the HCC group was
achieved by TNFa, GST-a and aFP (Table 3). The TNFa,
EGF and EGFR gave the best sensitivities and speciﬁcities
for HCC versus the HCV group and the TNFa, EG-
F,EGFR, GST-a and aFP were the best for the HCC versus
HBV group (Table 4). The best sensitivities and speciﬁcities
for HCC versus the Schist group and HCC versus Cirr
were obtained by TNFa, EGFR, GST-a, EGF and aFP
(Table 5).ups under investigation.
V HBV Cirr* HCC
40 40 40
34 36 36
6 4 4
9 42 ± 7.2 48.9 ± 5.4 53.4 ± 12.8
60) (30–55) (40–60) (28–80)
± 28.9 90 ± 19.2 63 ± 42.1 198.3 ± 122.3
129) (24–130) (70–152) (68–64.4)
17.6 34.4 ± 13.1 90.1 ± 24.1 79.5 ± 101.3
83) (13–63) (118–190) (8–461)
19.6 104.6 ± 19.4 30.1 ± 18.2 47.9 ± 38.8
7) (60–160) (1.8–87) (4–177)
0.7 4.9 ± 1.9 1.3 ± 1.8 2.2 ± 1.3
–2.9) (2.2–10.5) (0.1–7.5) (0.1–6.0)
0 0 13
40 0 6
0 0 1
4 8 29
9
26
5
ctively.
Table 3 AUC, cut-off values, sensitivity and speciﬁcity of different markers for HCC versus control and benign liver diseases.
HCC vs. control HCC vs. benign diseases
AUC Cut-oﬀ Sensitivity (%) Speciﬁcity (%) AUC Cut-oﬀ Sensitivity (%) Speciﬁcity (%)
TNF-a (pg/ml) 1.000 P120.0 100 100 0.992 P214.5 100 97.1
EGF (pg/ml) 0.944 6100.0 92.5 94.1 0.876 P69.0 97.5 89.3
EGFR (fm/ml) 1.000 6375.0 100 100 0.903 P279.0 97.5 89.3
GST-a (lg/l) 1.000 P18.5 100 100 0.956 P45.8 92.5 90.4
Iron (lg/ml) 0.775 691.4 77.5 76.5 0.730 690.2 77.5 71.8
Ferritin (lg/ml) 0.983 P227.5 97.5 94.1 0.508 P305.5 57.5 52.5
Transferrin (ng/ml) 0.974 6274.0 97.5 94.1 0.890 6232.5 90.0 77.4
a 1AT (ng/ml) 0.995 P243.8 97.1 94.1 0.884 P279.0 90.0 74.6
a FP (ng/ml) 1.000 P73.0 100 100 0.973 P158.0 91.4 89.2
AUC= area under the curve.
Table 2 The levels of different markers in sera of different groups under investigation.
Groups markers Control (n= 17) Schist (n= 40) HBV (n= 40) HCV (n= 40) Cirr (n= 40) HCC (n= 40) p-Value*
TNF-a (pg/ml) 19.4
(18.4–20.8)
32.0
(22.0–43.5)
65.5
(40.0–502.0)
119.5
(60.0–150.0)
171.0
(130.0–230.0)
301.0
(220.0–350.0)
<0.001
EGF (pg/ml) 106.0
(98.0–112.0)
27.8
(20.0–44.0)
14.0
(8.0–20.0)
40.0
(33.0–60.0)
21.3
(4.5–206.0)
89.0
(8.9–120.0)
<0.001
EGFR (fm/ml) 444.0
(410.0–494.0)
162.5
(16.5–180.0)
187.5
(152.0–225.0)
230.0
(190.0–260.0)
262.8
(224.0–280.0)
325.0
(275.0–340.0)
<0.001
GST-a (lg/l) 4.8
(3.4–6.0)
14.3
(10.5–20.0)
19.5
(9.0–80.0)
42.6
(28.0–78.0)
30.0
(20.0–45.5)
77.0
(31.0–191.0)
<0.001
Iron (lg/ml) 98.4
(69.5–132.5)**
32.4
(1.5–86.0)
189.0
(85.3–275.0)
188.1
(77.6–610.5)
208.6
(20.3–606.3)
80.4
(18.8–181.2)
<0.001
Ferritin (lg/ml) 200.0
(185.0–290.0)
242.5
(130.0–520.0)
387.5
(110.0–695.0)**
542.5
(220.0–800.0)
260.0
(130.0–550.0)**
315.0
(220.0–430.0)
<0.001
Transferrin (ng/ml) 290.0
(270.0–310.0)
202.5
(50.0–380.0)**
353.5
(205.0–630.0)
405.0
(185.0–700.0)
313.8
(205.0–450.0)
154.0
(50.0–402.0)
<0.001
a 1AT (ng/ml) 205.0
(170.0–278.0)
245.0
(82.5–337.5)
225.0
(99.0–392.5)
251.3
(185.5–368.0)
226.3
(95.0–336.0)
325.0
(227.5–381.0)
<0.001
a FP (ng/ml) 4.0
(2.0–6.0)
80.0
(7.0–220.0)
23.2
(10.0–152.0)
120.0
(10.0–320.0)
119.6
(54.0–165.0)
240.0
(140.0–396.0)
<0.001
Values expressed as median (range).
Pair-wise comparison with the post-hoc Dunnett test was done to compare all groups against HCC as a reference group.
* Kruskall Wallis test.
** No signiﬁcant difference with HCC group.
Table 4 AUC, cut-off values, sensitivity and speciﬁcity of different markers of HCC versus HCV and HBV.
Parameters HCC vs. HCV HCC vs. HBV
AUC Cut-oﬀ Sensitivity (%) Speciﬁcity (%) AUC Cut-oﬀ Sensitivity (%) Speciﬁcity (%)
TNF-a (pg/ml) 1.000 P185.0 100 100 0.967 P197.5 100 96.7
EGF (pg/ml) 0.975 P69.0 97.5 100 0.976 P49.0 97.5 100
EGFR (fm/ml) 1.000 P267.5 100 100 1.000 P250.0 100 100
GST-a (lg/l) 0.843 P54.5 80 70 0.987 P28.5 100 97.5
Iron (lg/ml) 0.963 6116.9 90 97.5 0.954 6120.5 90 87.5
Ferritin (lg/ml) 0.954 6397.5 90 90 0.703 6347.5 67.5 62.5
Transferrin (ng/ml) 0.974 6295.0 97.5 92.5 0.970 6272.5 97.5 85.0
a 1AT (ng/ml) 0.829 P307.5 70 70 0.849 P282.8 87.5 80.0
a FP (ng/ml) 0.916 P186.0 82.9 82.9 0.997 P141.0 97.1 97.2
AUC= area under the curve.
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Patients enrolled in this study were considered to be at high
risk for HCC, namely HBV and HCV infected individuals,schistosomal and cirrhotic patients. Chronic infective hepatitis
affects about 3% of the world population. It may lead to per-
sistent hepatocyte necro-inﬂammation and hepatic ﬁbrosis
[17], and is responsible for a large proportion of patients with
Table 5 AUC, cut-off values, sensitivity and speciﬁcity of different markers for HCC versus schistosomiasis and cirrhosis.
HCC vs. Schist HCC vs. Cirr
AUC Cut-oﬀ Sensitivity (%) Speciﬁcity (%) AUC Cut-oﬀ Sensitivity (%) Speciﬁcity (%)
TNF-a (pg/ml) 1.000 P131.8 100 100 0.997 P232.5 96.7 100
EGF (pg/ml) 0.975 P61.0 97.5 100 0.928 P64.0 97.5 95.0
EGFR (fm/ml) 1.000 P227.5 100 100 0.996 P283.8 97.5 100
GST-a (lg/l) 1.000 P25.5 100 100 0.976 P42.5 95.0 92.5
Iron (lg/ml) 0.893 P54.0 87.5 82.5 0.878 654.0 90.0 80.0
Ferritin (lg/ml) 0.810 P282.5 80.0 75.0 0.675 P292.5 72.5 67.5
Transferrin (ng/ml) 0.625 6154.5 52.5 62.5 0.957 6246.0 92.5 85.0
A1AT (ng/ml) 0.917 P278.8 90.0 85.0 0.893 P290.3 85.0 80.0
AFP (ng/ml) 0.978 P141.0 97.1 91.4 0.987 P158.0 91.4 94.3
AUC= area under the curve.
Biochemical markers in liver diseases 53cirrhosis that ends with HCC and that is mediated by different
cytokines [17,18]. The availability of suitable biochemical
markers to distinguish between HCC and benign liver lesions
would be very useful for early diagnosis. On the basis of the
heterogeneity of HCC, the current aim of this study is to dis-
cover an accurate and early diagnosis technique for HCC that
is based on the simultaneous measurement of a panel of highly
speciﬁc and sensitive markers, rather than measuring only one.
Accordingly, it is necessary to study the role of new biomark-
ers that might achieve this goal. Different markers with differ-
ent roles and mechanisms of action that proved to have an
impact on the growth of hepatocytes were thus selected. These
are pleiotropic inﬂammatory cytokine (TNF-a), growth factor
(EGF and EGFR), antioxidant (GST-a), markers of iron and
related proteins (iron, ferretin and transferrin), a protein syn-
thesized in the liver (a1AT), in addition to the classical marker
aFP.
The present results indicates that TNF-a has a potential
role in diagnosing and distinguishing different liver diseases
as its value increases in the following order HCC>HBV>
HCV> cirrhosis > schistosomiasis. These results are in
agreement with previous studies that revealed elevation of cir-
culating TNF-a level in HCC patients [19]. Byl et al. [20]
relate the rise in aspartate transferase to the increased release
of TNF-a and IL-1 from Kupffer cells of the liver. It is worth
mentioning that Maki et al. [21] report that inﬂammatory
by-products caused by HBV or HCV infection and TNF-a de-
rived from Kupffer cells produce oxygen-derived free radicals
and reactive oxygen species. These compounds mediate hepatic
ﬁbro genesis and liver injury [21,22]. The TNF-a may also
induce the production of other factors that contribute to
HCC [18]. Jeng et al. [19] report that TNF-a correlates with
disease severity and hepatoﬁbrosis, which may contribute to
a high risk for HCC. Sensitivity and speciﬁcity of TNF-a for
discriminating between benign liver disorders and HCC were
100% and 97.1%, respectively, at a cut-offP 214.5 pg/ml.
Lower levels of TNF-a were highly sensitive and speciﬁc when
comparing HCC with controls. Accordingly, the present ﬁnd-
ings recommend TNF-a as a promising tumour marker for
HCC. Jeng et al. [19] report that TNF-a correlates with disease
severity and hepatoﬁbrosis, which may contribute to a high
risk for HCC. In addition, Ataseven et al. [23] found that ser-
um TNF-a signiﬁcantly increased in cirrhosis and HCC. It is
generally believed that increased endogenous TNF-a in ad-
vanced liver disease is a consequence of chronic liver failure,which is associated with endotoxin-dependent macrophage
stimulation and with a decrease in cytokine clearance [24].
In this study, the serum levels of EGF and its receptor sig-
niﬁcantly decreased in all the disease groups as compared with
the control group. These results coincide with those of Oguey
et al. [25] who observed that EGF was down-regulated in rat
liver cirrhosis. Burr et al. [26] demonstrated that the decrease
in EGFR is associated with decrease of EGF and increase in
TGF-a in rodent liver cancer models. However, patients in this
study with HCC had signiﬁcantly higher levels of EGF and
EGFR as compared with their corresponding levels in benign
liver diseases, but not with normal individuals. In fact, the var-
iation between groups was slight, which makes it difﬁcult to
distinguish between malignant and benign liver diseases.
Dash et al. [27] reported that populations at high risk for
liver cancer include those who have genetic polymorphism in
both microsomal epoxide hydrolase and GST. The levels of
these markers may help in identifying susceptible populations
in developing countries. All GST isoenzymes are expressed in
the liver with different proportions [28]. Many drug-resistance
genes such as GST, glycoprotein and heat-shock proteins are
expressed by HCC [29]. These data indicate that the determi-
nation of GST-a is very useful in the differentiation between
HCC and other chronic liver diseases. Previous studies have re-
ported that increased serum GST-a is a sensitive indicator of
acute liver damage [30]. Fernandes et al. [31], who observed
over expression of GST-a in sera of transgenic mice with
chronic hepatitis, report similar ﬁndings. In this study, GST-
a had 100% sensitivity and 100% speciﬁcity for differentiating
HCC from normal healthy individuals. These results also indi-
cate high sensitivities and speciﬁcities to discriminate between
HCC and each of the benign liver diseases that were enrolled in
the study.
Because the liver is an iron-rich organ that contains 30% of
total body storage [32], it is the most susceptible organ to cel-
lular damage, caused by the abrupt accumulation of iron. In
this study, iron ferritin and transferring were slightly elevated
in sera of patients with HBV, HCV and cirrhosis, as compared
with their corresponding values in sera of normal controls.
These data are in agreement with Kowdley [33] who reported
that viruses might directly up-regulate hepatic production of
the transferrin receptor or ferritin, leading to increased hepatic
iron deposition. These increases account for various mecha-
nisms in which iron mediates or modulates response to infec-
tion or inﬂammation. Ferrous iron is a catalyst for free
54 N.I. Zakhary et al.radical formation and lipid peroxidation, which are known to
occur in different tissue. El-Atrebi [34] found that there were
elevations in serum iron, ferritin and transferrin concentration
in patients with the hepatitis C virus. On the other hand, this
study revealed lower levels of serum iron and transferrin in
both schistosomiasis and HCC groups than in the control
group. These results are in agreement with Farag et al. [35].
However, the variation in the levels of iron, ferretin and trans-
ferrin obtained in this study are not sufﬁcient to diagnose HCC
or other liver diseases. Consequently, the three markers had
weak sensitivity and speciﬁcity for distinguishing HCC from
benign liver diseases.
Similarly, serum alpha-1-antitrypsin did not add much for
differentiating HCC from benign liver diseases despite its sig-
niﬁcantly higher levels compared to chronic liver disease
groups. This is obvious from its low sensitivity and speciﬁcity.
In this respect, it is worth mentioning that El-Asqalani [36]
found that a1AT serum levels were signiﬁcantly increased in
HCC and other types of malignant liver tumours as compared
with normal controls. Alternatively, a high a1AT value may
simply reﬂect a non-speciﬁc acute-phase response associated
with tissue injury [37].
More than 70% of HCC patients have high serum levels of
aFP. Those with values over 400 ng/ml tend to have greater tu-
mour size, bilobular involvement, massive diffuse type, portal
vein thrombosis and lower median survival rate. In spite of
that, some reports implicate its limited utility in differentiating
HCC from benign hepatic disorders for its high false-negative
rates [38], This study revealed a signiﬁcant increase in aFP ser-
um levels in HCC patients. Other benign liver diseases such as
schistosomiasis, hepatitis and cirrhosis also showed elevated
levels of the protein, but it was still signiﬁcantly lower than
that of HCC. Silver et al. [39] conﬁrmed that there is a strong
relationship between viral hepatitis and aFP production. They
also observed that aFP synthesis was related to higher aspar-
tate transferase levels and a lack of uniform destruction and re-
pair that occurs during the hepatitis process or schistosomal
infestation. In this study, the aFP at a level of P158.0 ng/ml
had a 91.4% sensitivity and 89.2% speciﬁcity to distinguish
HCC from other benign hepatic lesions. However, several
investigators concluded that aFP fails as a reliable marker,
mainly because it shows poor sensitivity, ranging from 39%
to 65% and a speciﬁcity ranging from 76% to 97% [40].Conclusions
This study found that it is advisable to carry out a battery of
markers composed of aFP, TNF-a and GST-a to conﬁrm
the diagnosis of HCC and distinguish it from other benign li-
ver diseases, namely HCV, HBV, schistosomiasis and cirrhosis.
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